{"classes":[{"categories":[{"measurements":[{"comment":"Median duration or response and CI are not able to be estimated due to a low number of progression or death events","groupId":"OG000","lowerLimit":"NA","upperLimit":"NA","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"}],"units":"Participants"}],"description":"Duration of response (DOR) is defined as time from date at which the patient's confirmed objective status is noted to the earliest date of progression or death. The DOR will be estimated using the method of Kaplan-Meier.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients receive carfilzomib IV over 30 minutes on days 1, 8, and 15 and daratumumab IV on days 1 and 2 of cycle 1 then days 8, 15, and 22 of cycle 1, then, days 1, 8, 15, and 22 of cycle 2, days 1 and 15 of cycles 3-6, and day 1 of subsequent cycles. Patients also receive dexamethasone PO on days 1, 8 15, and 22, and selinexor PO on days 1, 8, and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.\\>\n\n\\> Carfilzomib: Given IV\\>\n\n\\> Daratumumab: Given IV\\>\n\n\\> Dexamethasone: Given PO\\>\n\n\\> Quality-of-Life Assessment: Ancillary studies\\>\n\n\\> Selinexor: Given PO","id":"OG000","title":"Treatment (Carfilzomib, Daratumumab, Dexamethasone, Selinexor)"}],"paramType":"MEDIAN","populationDescription":"Only patients with a confirmed response are included in analysis","reportingStatus":"POSTED","timeFrame":"2 years","title":"Duration of Response","type":"SECONDARY","unitOfMeasure":"months"}